Knight Therapeutics Inc
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for p… Read more
Knight Therapeutics Inc (KHTRF) - Net Assets
Latest net assets as of September 2025: $767.82 Million USD
Based on the latest financial reports, Knight Therapeutics Inc (KHTRF) has net assets worth $767.82 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.05 Billion) and total liabilities ($282.18 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $767.82 Million |
| % of Total Assets | 73.13% |
| Annual Growth Rate | 5.2% |
| 5-Year Change | -10.28% |
| 10-Year Change | 23.84% |
| Growth Volatility | 19.45 |
Knight Therapeutics Inc - Net Assets Trend (2014–2024)
This chart illustrates how Knight Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Knight Therapeutics Inc (2014–2024)
The table below shows the annual net assets of Knight Therapeutics Inc from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $795.11 Million | +6.46% |
| 2023-12-31 | $746.87 Million | -9.56% |
| 2022-12-31 | $825.86 Million | -1.92% |
| 2021-12-31 | $842.02 Million | -4.99% |
| 2020-12-31 | $886.24 Million | -3.15% |
| 2019-12-31 | $915.11 Million | -11.16% |
| 2018-12-31 | $1.03 Billion | +3.92% |
| 2017-12-31 | $991.21 Million | +1.17% |
| 2016-12-31 | $979.72 Million | +52.59% |
| 2015-12-31 | $642.06 Million | +34.04% |
| 2014-12-31 | $478.99 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Knight Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 15479400000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $154.79 Million | 19.47% |
| Common Stock | $534.27 Million | 67.19% |
| Other Comprehensive Income | $80.22 Million | 10.09% |
| Other Components | $25.82 Million | 3.25% |
| Total Equity | $795.11 Million | 100.00% |
Knight Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Knight Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang Baida Precision Mnfg
SHG:603331
|
$270.21 Million |
|
Suzhou W Deane New Power Elec
SHG:603312
|
$270.25 Million |
|
Suwen Electric Energy Technology Co.Ltd
SHE:300982
|
$270.26 Million |
|
Ginkgo Bioworks Holdings
NYSE:DNA
|
$270.35 Million |
|
ACAST AB (PUBL)
F:0PN
|
$270.11 Million |
|
Tellgen Corp
SHE:300642
|
$270.07 Million |
|
Bosung Power Technology Co. Ltd
KQ:006910
|
$270.01 Million |
|
Sinosteel Luonai Materials Technology Co. Ltd. A
SHG:688119
|
$270.01 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Knight Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 746,871,000 to 795,105,000, a change of 48,234,000 (6.5%).
- Net income of 4,332,000 contributed positively to equity growth.
- Share repurchases of 8,866,000 reduced equity.
- Other comprehensive income increased equity by 50,391,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $4.33 Million | +0.54% |
| Share Repurchases | $8.87 Million | -1.12% |
| Other Comprehensive Income | $50.39 Million | +6.34% |
| Other Changes | $2.38 Million | +0.3% |
| Total Change | $- | 6.46% |
Book Value vs Market Value Analysis
This analysis compares Knight Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.56x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 35470712.71x to 0.56x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.00 | $4.39 | x |
| 2014-12-31 | $8.36 | $4.39 | x |
| 2015-12-31 | $6.65 | $4.39 | x |
| 2016-12-31 | $8.08 | $4.39 | x |
| 2017-12-31 | $6.91 | $4.39 | x |
| 2018-12-31 | $7.19 | $4.39 | x |
| 2019-12-31 | $5.79 | $4.39 | x |
| 2020-12-31 | $6.71 | $4.39 | x |
| 2021-12-31 | $6.76 | $4.39 | x |
| 2022-12-31 | $7.19 | $4.39 | x |
| 2023-12-31 | $6.95 | $4.39 | x |
| 2024-12-31 | $7.85 | $4.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Knight Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.17%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.21x
- Recent ROE (0.54%) is below the historical average (3.59%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 26.28% | 34451.40% | 0.00x | 1.02x | $77.96 Million |
| 2015 | 5.32% | 3294.79% | 0.00x | 1.01x | $-30.04 Million |
| 2016 | 1.89% | 312.46% | 0.01x | 1.01x | $-79.41 Million |
| 2017 | 1.74% | 199.72% | 0.01x | 1.01x | $-81.88 Million |
| 2018 | 2.34% | 192.63% | 0.01x | 1.02x | $-78.92 Million |
| 2019 | 1.79% | 30.59% | 0.04x | 1.61x | $-66.56 Million |
| 2020 | 3.58% | 15.92% | 0.19x | 1.17x | $-56.86 Million |
| 2021 | 1.86% | 6.44% | 0.25x | 1.18x | $-68.53 Million |
| 2022 | -3.62% | -10.18% | 0.28x | 1.28x | $-112.48 Million |
| 2023 | -2.25% | -5.13% | 0.35x | 1.27x | $-91.52 Million |
| 2024 | 0.54% | 1.17% | 0.39x | 1.21x | $-75.18 Million |
Industry Comparison
This section compares Knight Therapeutics Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $439,452,927
- Average return on equity (ROE) among peers: -31.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Knight Therapeutics Inc (KHTRF) | $767.82 Million | 26.28% | 0.37x | $270.15 Million |
| Ascend Wellness Holdings Inc (AAWH) | $71.80 Million | -118.37% | 11.54x | $48.90 Million |
| AB Science S.A (ABSCF) | $-21.01 Million | 0.00% | 0.00x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $-294.68K | 0.00% | 0.00x | $603.58K |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -156.52% | 0.78x | $195.20 Million |
| Acreage Holdings Inc (ACRDF) | $494.79 Million | -30.37% | 0.40x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $29.91 Million | 0.00% | 0.07x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.72 Million | -18.78% | 0.11x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $20.08 Million | -10.91% | 0.33x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $21.19 Million | 12.93% | 1.96x | $1.85 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.25 Billion | 5.19% | 0.72x | $85.61 Million |